Replies to post #561429 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

The reality is, regardless of what you say, it is irrelevant to the concrete reality of their success and what is coming. They are tiny, obscure, and the study is old. They are women, one a minority woman, and they seem not to have broken through the cheer squad level of coverage. I think they have not spend enough time on their national coverage effort, though no doubt the wrong people think they have, but I also think they just have their heads down and are focused on the work of getting to market. They are thinly staffed and it takes a bigger organization and more resources perhaps to skillfully execute a powerful media strategy as well. I just think it is not in their skill set.

[hoffmann6383]

Read this:

Delighted that the Editorial Board of @NeurologyToday, the news source of the AAN, @AANmember, selected our dendritic cell vaccine trial, led by Dr. Linda Liau, as one of the "Best Advances of 2022." #immunotherapy @PennNeurology @PennNSG @PennCancer https://t.co/U8ML7OCOBR

— Steven Brem (@StevenBremMD) January 22, 2023

[Roman516]

TLD is in, and the publication information is great, plus many doctors, scientist, and professional all find it compelling. The media is starting to take notice and coming out to accept DCVax-L. The JAMA Oncology Comments support DCVax-L as well. OTCs do in fact have credibility, and NWBO is has credibility as well. NWBO has a product that works and will be a great story.